Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects
Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects
The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B & C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.
Inclusion Criteria:
Exclusion Criteria:
Basking Ridge, New York 07920, United States
B-leuven, 3000, Belgium
Hospitalet Llobregat- Barcelona, 9908, Spain
Majadahonda - Madrid, 28222, Spain